DGAP-News: Willkie Farr&Gallagher LLP: Willkie advises AXA Private Equity on the acquisition of Riemser Arzneimittel AG
(firmenpresse) - DGAP-News: Willkie Farr&Gallagher LLP / Key word(s): Private Equity
Willkie Farr&Gallagher LLP: Willkie advises AXA Private Equity on
the acquisition of Riemser Arzneimittel AG
21.08.2012 / 17:35
---------------------------------------------------------------------
AXA Private Equity, the leading European diversified private equity firm,
has acquired Riemser Arzneimittel AG (Riemser), an international specialty
pharmaceutical company, headquartered in Greifswald, Germany.
AXA Private Equity has acquired the shareholdings of Riemser's founding
Braun family and those of various minority stakeholders, including TVM
Capital. The completion of the transaction remains subject to approval by
the German competition authority.
Riemser operates internationally and has a primary focus on the sales,
marketing and lifecycle management of pharmaceutical products for niche
therapeutic markets with high medical need in the fields of Oncology,
Anti-Infectives and Dermatology. In 2011, Riemser, which has around 500
employees on its payroll, posted sales revenues of approximately EUR100
million and continues to grow profitably.
Christof Naményi, Managing Director of AXA Private Equity, said: 'Riemser
Arzneimittel AG is characterized by an increasing strategic focus on
specialist niche therapeutic markets and is successfully pursuing an
international growth strategy. With our global network, we will be actively
supporting the strategy of continued specialization and
internationalization which has been pursued by our management.'
Dr. Michael Mehler, CEO of Riemser, added: 'We are delighted to have found
in AXA Private Equity a strong partner with whom we can continue our growth
strategy systematically. The measures adopted over the past few years -
such as internationalization and the increased specialization and
strengthening of our product portfolio in selected therapeutic areas - have
been the right steps on our path towards a successful future.'
The Willkie team was led by Dr. Andreas Hautkappe (Corporate/Private
Equity) and included the partners Mario Schmidt, Dr. Stefan Joergens, Georg
Linde (Corporate/Private Equity), Jan Wilms (Finance), Rolf Huenermann
(Antitrust/Corporate Compliance), Dr. Christian Rolf (HR) and the
associates Dr. Octávio de Sousa (Corporate/Private Equity), Mario Bammann
(Finance), Johannes Eckhardt (Corporate/Private Equity), Tobias Daubert
(Finance), Christina Mann (Corporate/Private Equity), Wolfgang Münchow
(Corporate), Jochen Riechwald (HR), Dr. Stephanie Schmidt-Ehemann
(Corporate/Restructuring), Patrick Wacker (Corporate/Private Equity) and
Daniel Zakrzewski (Corporate/Private Equity).
Willkie Farr&Gallagher LLP is an international law firm, comprising more
than 650 attorneys with offices in New York, Washington, Paris, London,
Milan, Rome Frankfurt and Brussels. The headquarters are in New York, 787
Seventh Avenue, Tel.: 001 212 728 8000.
Frankfurt, August 21, 2012
End of financial news
---------------------------------------------------------------------
21.08.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive atwww.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
182409 21.08.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 21.08.2012 - 17:35 Uhr
Sprache: Deutsch
News-ID 176415
Anzahl Zeichen: 3995
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 422 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Willkie Farr&Gallagher LLP: Willkie advises AXA Private Equity on the acquisition of Riemser Arzneimittel AG"
steht unter der journalistisch-redaktionellen Verantwortung von
Willkie Farr&Gallagher LLP (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
